Virus-like particle vaccinology, from bench to bedside.

Mohsen, Mona O; Bachmann, Martin F (2022). Virus-like particle vaccinology, from bench to bedside. Cellular & molecular immunology, 19(9), pp. 993-1011. Nature Publ. Group 10.1038/s41423-022-00897-8

Preview

Text s41423-022-00897-8.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (3MB) | Preview

Virus-like particles (VLPs) have become key tools in biology, medicine and even engineering. After their initial use to resolve viral structures at the atomic level, VLPs were rapidly harnessed to develop antiviral vaccines followed by their use as display platforms to generate any kind of vaccine. Most recently, VLPs have been employed as nanomachines to deliver pharmaceutically active products to specific sites and into specific cells in the body. Here, we focus on the use of VLPs for the development of vaccines with broad fields of indications ranging from classical vaccines against viruses to therapeutic vaccines against chronic inflammation, pain, allergy and cancer. In this review, we take a walk through time, starting with the latest developments in experimental preclinical VLP-based vaccines and ending with marketed vaccines, which earn billions of dollars every year, paving the way for the next wave of prophylactic and therapeutic vaccines already visible on the horizon.

Interest & Impact

Downloads

281 since deposited on 17 Aug 2022
73 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item